E
GTHX

Ergoteles’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Ergoteles’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-115,751
Closed -$629K – 1862
2022
Q4 		$629K Buy
+115,751
New +$970K 0.02% 617
2022
Q3 		– Sell
-220,100
Closed -$1.09M – 2098
2022
Q2 		$1.09M Buy
220,100
+183,900
+508% +$1.02M 0.03% 516
2022
Q1 		$275K Buy
36,200
+3,446
+11% +$32.7K 0.01% 874
2021
Q4 		$334K Sell
32,754
-18,013
-35% -$230K 0.01% 813
2021
Q3 		$681K Buy
+50,767
New +$827K 0.03% 479

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ergoteles's GTHX Position: Q1 2023 in Review

Ergoteles sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2023, closing a stake of 115,751 shares — an estimated $629K sold.

Ergoteles first reported a position in GTHX in Q3 2021 and held it in 5 quarters. The position peaked at $1.09M in Q2 2022. 96 funds tracked by Wall St. Rank hold GTHX as of Q1 2023.

  • Ergoteles reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 115,751 G1 Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $629K.
  • Ergoteles first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2021 and held it in 5 quarters.
  • Ergoteles's G1 Therapeutics, Inc. Common Stock position peaked at $1.09M in Q2 2022.
  • 96 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.